6/7/2010

Pfizer's experimental drug crizotinib reduced tumors in a majority of patients with advanced nonsmall-cell lung cancer who possess a specific genetic abnormality, U.S. researchers reported. Crizotinib inhibits a mutation that produces the carcinogenic gene EML4-ALK.

Full Story:
Reuters

Related Summaries